Article Text

PDF
Targeted therapies: summary clinical trials working group
  1. M E Weinblatt1,
  2. P L C M van Riel2
  1. 1Brigham and Women’s Hospital, Boston, MA, USA
  2. 2University Medical Center Nijmegen, Nijmegen, the Netherlands
  1. Correspondence to:
    P L C M van Riel
    p.vanriel{at}reuma.umcn.nl

Statistics from Altmetric.com

During the Symposium on Advances in Targeted Therapies two groups met to discuss issues regarding clinical trials in rheumatoid arthritis. This has been a most eventful time for rheumatology. In the past decade six biological response modifiers have been approved. There has been universal acceptance of earlier intervention to treat this disease and the success of combination therapies. And we have evidence that measuring disease activity quantitatively and adjusting drug therapy based on these measurements can improve the course of the disease, resulting in a better outcome for the patients with regard to, for instance, functional capacity and quality of life.

However, despite the significant advances in the treatment of rheumatoid arthritis, remission still is generally not an achievable goal. The discussion during this meeting addressed issues regarding current trial design …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.